Loading…
Loading…
Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving positive momentum post-earnings.
Thomson Reuters is rated 'Buy' after a 10% post-earnings dip, despite robust revenue growth and raised guidance. TRI's recurring revenue rose 9% YoY, now 82% of total, with AI-enabled products driving commercial momentum and portfolio transition. Its forward P/E is well below TRI's historical average, supporting double-digit total return potential.
TC Energy is upgraded from 'Hold' to 'Buy' based on robust Q2 results and a clear growth outlook. TRP delivered 12% YoY comparable EBITDA growth, driven by high utilization across the U.S., Mexico, and power segments. It maintains a BBB+ credit rating, 4.75x debt/EBITDA, and a 3.8% yield, supporting continued dividend growth.
Procter & Gamble is trading near its 52-week low, offering a 3% dividend yield and a forward P/E of 20.6x, below its 10-year average. PG demonstrates resilient earnings, a strong brand portfolio, and innovation-led growth, especially in China and Latin America, despite recent consumer demand headwinds. AI-driven innovation and supply chain upgrades position the company for EPS growth and improved productivity, with catalysts not fully priced in.
Hormel is reaffirmed as a "Buy" for its resilient organic growth, margin expansion, and defensive income profile. HRL delivered 3% YoY organic sales growth and 14% adjusted EPS growth in Q2, outperforming the S&P 500 year-to-date. Operational improvements, a strong balance sheet, and a 4.6% dividend yield support the investment case at a 17.3x forward P/E.
Passive income has a way of quieting the noise. Whether markets are grinding higher, correcting hard, or drifting sideways, a dividend check lands in your account on the schedule the company sets, regardless of what the stock is doing.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring.
PepsiCo, Inc. and Badger Meter, Inc. are high-quality dividend stocks trading below historical averages, offering compelling medium- to long-term upside. PEP faces near-term margin pressure from inflation but expects improved cash flow and growth from acquisitions like Poppi, with analysts targeting $200 by 2028. BMI's share price correction and debt-free balance sheet position it for growth via bolt-on acquisitions, with double-digit EPS growth expected from 2027 onward.
No recent filings indexed.